These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 8692980)
1. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Burfeind P; Chernicky CL; Rininsland F; Ilan J; Ilan J Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7263-8. PubMed ID: 8692980 [TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Damon SE; Plymate SR; Carroll JM; Sprenger CC; Dechsukhum C; Ware JL; Roberts CT Endocrinology; 2001 Jan; 142(1):21-7. PubMed ID: 11145562 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular smooth muscle cell growth through antisense transcription of a rat insulin-like growth factor I receptor cDNA. Du J; Delafontaine P Circ Res; 1995 Jun; 76(6):963-72. PubMed ID: 7758167 [TBL] [Abstract][Full Text] [Related]
4. Loss of tumorigenicity of rat glioblastoma directed by episome-based antisense cDNA transcription of insulin-like growth factor I. Trojan J; Blossey BK; Johnson TR; Rudin SD; Tykocinski M; Ilan J; Ilan J Proc Natl Acad Sci U S A; 1992 Jun; 89(11):4874-8. PubMed ID: 1594587 [TBL] [Abstract][Full Text] [Related]
5. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression. Grzmil M; Hemmerlein B; Thelen P; Schweyer S; Burfeind P J Pathol; 2004 Jan; 202(1):50-9. PubMed ID: 14694521 [TBL] [Abstract][Full Text] [Related]
6. Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells. Rininsland F; Johnson TR; Chernicky CL; Schulze E; Burfeind P; Ilan J Proc Natl Acad Sci U S A; 1997 May; 94(11):5854-9. PubMed ID: 9159164 [TBL] [Abstract][Full Text] [Related]
7. Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I. Chernicky CL; Yi L; Tan H; Ilan J Clin Breast Cancer; 2005 Oct; 6(4):340-8. PubMed ID: 16277885 [TBL] [Abstract][Full Text] [Related]
8. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo. Chernicky CL; Tan H; Yi L; Loret de Mola JR; Ilan J Mol Pathol; 2002 Apr; 55(2):102-9. PubMed ID: 11950959 [TBL] [Abstract][Full Text] [Related]
9. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Nakamura K; Hongo A; Kodama J; Miyagi Y; Yoshinouchi M; Kudo T Cancer Res; 2000 Feb; 60(3):760-5. PubMed ID: 10676665 [TBL] [Abstract][Full Text] [Related]
10. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Lee CT; Wu S; Gabrilovich D; Chen H; Nadaf-Rahrov S; Ciernik IF; Carbone DP Cancer Res; 1996 Jul; 56(13):3038-41. PubMed ID: 8674059 [TBL] [Abstract][Full Text] [Related]
11. Prevention of metastasis by inhibition of the urokinase receptor. Crowley CW; Cohen RL; Lucas BK; Liu G; Shuman MA; Levinson AD Proc Natl Acad Sci U S A; 1993 Jun; 90(11):5021-5. PubMed ID: 8389464 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-1 receptor. Pass HI; Mew DJ; Carbone M; Matthews WA; Donington JS; Baserga R; Walker CL; Resnicoff M; Steinberg SM Cancer Res; 1996 Sep; 56(17):4044-8. PubMed ID: 8752177 [TBL] [Abstract][Full Text] [Related]
13. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Resnicoff M; Sell C; Rubini M; Coppola D; Ambrose D; Baserga R; Rubin R Cancer Res; 1994 Apr; 54(8):2218-22. PubMed ID: 8174129 [TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin. Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of rat C6 glioblastoma tumor growth by expression of insulin-like growth factor I receptor antisense mRNA. Resnicoff M; Li W; Basak S; Herlyn D; Baserga R; Rubin R Cancer Immunol Immunother; 1996 Jan; 42(1):64-8. PubMed ID: 8625368 [TBL] [Abstract][Full Text] [Related]
16. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Chernicky CL; Yi L; Tan H; Gan SU; Ilan J Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344 [TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Koutsilieris M; Frenette G; Lazure C; Lehoux JG; Govindan MV; Polychronakos C Anticancer Res; 1993; 13(2):481-6. PubMed ID: 7685989 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Scotlandi K; Maini C; Manara MC; Benini S; Serra M; Cerisano V; Strammiello R; Baldini N; Lollini PL; Nanni P; Nicoletti G; Picci P Cancer Gene Ther; 2002 Mar; 9(3):296-307. PubMed ID: 11896447 [TBL] [Abstract][Full Text] [Related]
19. [Abnormal expression of insulin-like growth factor-I receptor and inhibitory effect of its transcription intervention on nude mice xenograft tumor]. Yao M; Yan XD; Cai Y; Gu JJ; Yang XL; Pan LH; Wang L; Yao DF Zhonghua Gan Zang Bing Za Zhi; 2016 Nov; 24(11):846-851. PubMed ID: 27978931 [No Abstract] [Full Text] [Related]